SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Gene Voss who wrote (5165)1/31/1998 8:06:00 AM
From: RT  Read Replies (2) | Respond to of 23519
 
Gene,

Would you please explain in detail why HVSF could not be a major threat to Vivus's transurethal approach.

My understanding of HVSF product is that:

1. Easier to use. (smaller applicator)
2. No irratation
2. Needs no refrigeration

So why would Vivus, be the product of choice for transurethal delivery if such claims are true and Vivus's patent is breached.

Deeply Concerned,

RT



To: Gene Voss who wrote (5165)1/31/1998 9:26:00 AM
From: Tunica Albuginea  Read Replies (1) | Respond to of 23519
 
Gene, let me guess: Alprostadil and Minoxidl, gg. That ought to put you in orbit gg.

TA


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News